Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

PAH is a life-threatening disease, caused by the narrowing of blood vessels in the lungs, which is currently treated mainly with drugs that dilate the blood vessels, like endothelin antagonists ...

Pulmonary Arterial Hypertension (PAH) is an often-overlooked yet life-altering disease that affects thousands globally, requiring lifelong management, rigorous monitoring, and substantial emotional ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...